NCT03025035View on ClinicalTrials.gov

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 10, 2017

Primary Completion Date

October 8, 2024

Study Completion Date

August 8, 2026

Conditions
Breast Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab IV solution administered on Day 1 of each 3-week cycle

DRUG

Olaparib

Olaparib administered orally twice a day

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yuan Yuan

OTHER